- Cytolon and T-Cell Europe agree on cooperation
- Cytolon initiates global development of DIT - Distributed-Inventory-TechnologyTM
- Cytolon joins Personalized Medicine Coalition
- Cytolon successful with second financing round
- Cytolon gains Patent for CordMatch® in Australia
- Cytolon and DKMS Cord Blood Bank announce collaboration for CordMatch’s Beta-Testing Phase
- Timm Jessen Joins Cytolon’s Supervisory Board
- Cytolon Partners with iSoft for New Life Science Research Tool
- Michaela Servas joins Cytolon´s Supervisory Board
- Cytolon Co-Founder Prof. Dr. Joachim Dudenhausen receives Order of Merit
- CordMatch® goes live
- Cytolon Partners with CSC to Develop CordMatch®
- Cytolon Closes Its First Round of Financing
- Wolfgang Jünger Joins Cytolon's Supervisory Board
- Katherina Reiche, MdB, Steps Down From Cytolon's Supervisory Board to Become a Member of the Federal Government of Germany
- Cytolon Receives the "MOST PROMISING COMPANY LAUNCHED IN 2009 AWARD"
- Cytolon Announces Cooperative Agreement with ARCWAY
- Start-up Financing Begins
- The Launching of Cytolon AG
Wolfgang Jünger Joins Cytolon's Supervisory Board
Berlin, December 2nd 2009 – Cytolon AG announced today that Wolfgang Jünger has accepted an appointment to the company's Supervisory Board. Wolfgang Jünger is an entrepreneur, management consultant and investor. He has been a senior partner of a leading US consulting firm responsible for global small to mid-sized corporate finance transactions. Since then, he has held several management positions in business development and finances in industry, as well as engaging in own industrial investments in Asia.
Thomas Klein, Cytolon's Founder and Chief Executive Officer, stated "we are proud that Mr. Jünger has accepted a position on Cytolon's Supervisory Board. His outstanding expertise as an entrepreneur and management consultant is a great asset for this company."
Wolfgang Jünger stated "I am extremely excited to be part of Cytolon's project, which I am sure will become a milestone in the development of personalized healthcare services for the time-critical treatment of a large number of patients".
Detailed biographies of each member of the Supervisory Board are available on our website at www.cytolon.com, the content of which is not part of this press release.
About Cytolon AG:
Cytolon AG is a private Company based in Berlin, Germany that has developed a proprietary, patent-pending, global, internet-based cord blood brokering platform termed CordMatch®. This platform is positioned to profit from the crossroad of the personal data and cellular therapeutic markets of regenerative medicine. Cytolon's mission is to be the world's first trusted source for getting the correct, best-matched cord blood unit (CBU) to the patient that needs it in a timely manner. An accurate cord blood matching platform is imperative as a CBU must accurately match the histocompatibility antigens and the genetic needs of the patient. Cytolon provides solutions and services for today and the future so world-wide transplant centers can talk efficiently and effectively to world-wide cord blood banks, registries, industry partners and service providers. Cytolon focuses on penetrating immediate and emerging markets in the cord blood and stem cell area. For more information, please visit the company's Web site at www.cytolon.com.
Contact:
Nina Hofle - PR Manager
Cytolon AG
Am Karlsbad 15
10785 Berlin - Germany
phone: +49 (0) 30 2639 288-0
fax: +49 (0) 30 2639 288-20
e-mail: info@cytolon.com
web: www.cytolon.com